查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1493242

生物技術和製藥服務外包市場規模、佔有率和趨勢分析報告：按服務、最終用途、地區、細分市場預測，2024-2030 年

Biotechnology And Pharmaceutical Services Outsourcing Market Size, Share & Trends Analysis Report By Service (Consulting, Auditing & Assessment), By End-use (Pharmaceutical Companies, Biotech Companies), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

生物技術和製藥服務外包市場成長和趨勢：

Grand View Research, Inc.最新報告顯示，預計到2030年，全球生物技術和醫藥服務外包市場規模將達到669.5億美元，2024年至2030年複合年成長率為5.67%。

製藥和生物技術公司增加對創新療法的研發投資，這需要複雜而嚴格的時間表跟進，正在推動該行業的外包趨勢。此外，在生物技術和製藥行業，由於開發新藥的成本較高，客戶更喜歡具有成本效益的外包解決方案。 CRO 擁有必要的專業知識和基礎設施，可提供成本、時間和效率優勢。此外，日本、印度和中國等新興國家因其豐富的專業知識、研發基礎設施和實惠的價格而成為外包的首選目的地。

此外，一些國家有複雜的藥物發現和發展法律規範。因此，藥物開發各領域對專業知識的需求不斷增加，對外包服務的需求不斷增加。製藥公司不僅外包藥品生產，還外包臨床試驗。此外，臨床試驗的日益私有化正在增加製造業務向中國、印度和拉丁美洲等新興國家的外包。此外，隨著臨床試驗的全球化，對外包服務的需求不斷增加，特別是在拉丁美洲和中東/非洲等新興市場，由於患者數量多、成本低。

監管核准程序變得更加嚴格和耗時，公司的目標是一次性獲得產品核可，以佔領更高的市場佔有率。由於已開發國家嚴格的監管要求以及新興國家不斷變化的監管規定，製藥和生物技術公司必須要么擁有內部監管部門，要么將其監管業務外包。因此，企業根據計劃規模和優先順序採用不同的外包模式，有助於全球生物技術/製藥服務外包市場的成長。

製藥和生物技術公司現在透過專注於核心能力和外包非核心職能來提高生產力和業務效率。這些公司通常將研發職能外包給亞太地區等新興地區，現在開始將產品設計和開發外包給CRO，以降低成本並專注於核心職能。沒有內部能力的中小企業必須將產品設計和開發、審核和監管業務外包，才能進入新市場。中小型企業和專業公司聘請 CRO 顧問來協助其在國際市場上的監管業務和法律代表職能。

生物技術和製藥服務外包市場報告亮點

  • 從服務來看，諮詢領域將在 2023 年佔據市場主導地位。由於美國FDA 和 EMA 等多個監管機構的監管變化不斷增加，製藥和生物技術公司對監管合規的需求不斷成長，推動了該行業的快速成長。為了確保遵守不斷變化的法規，如果產品不符合監管標準，製藥和生技產品可能會面臨撤回、召回、重新包裝和重新標籤的情況。
  • 按最終用途分類，製藥公司板塊佔據了大部分收益佔有率，2023年佔超過58.44%。該行業的成長部分歸因於製藥公司擴大外包監管服務以及產品設計和開發服務，以避免高資本支出並提高利潤率。
  • 2023 年，亞太地區以 42.41% 的佔有率佔據市場主導地位。該地區的成長得益於已開發國家研發投資的激增以及臨床試驗評估的一系列監管改革，以符合該地區每個投資國家的監管指南。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第 3 章生物技術和製藥服務外包市場變數、趨勢和範圍

  • 市場體系展望
  • 市場動態
  • 技術景觀
  • 定價模式分析
  • 臨床試驗量分析
  • 研發投入分析
  • 生技與製藥服務外包市場分析工具
  • COVID-19 影響分析

第4章生技與醫藥服務外包市場：服務評估與趨勢分析

  • 細分儀表板
  • 生技與醫藥服務外包市場：服務變化分析
  • 2018-2030年全球生技及製藥服務外包市場規模及趨勢分析（依服務）
  • 諮詢
  • 監管業務
  • 產品設計與開發
  • 審核與評估
  • 產品維護
  • 培訓和教育
  • 其他

第5章生物技術和製藥服務外包市場：最終用途估計和趨勢分析

  • 細分儀表板
  • 生物技術和製藥服務外包市場：最終用途變化分析
  • 2018-2030 年全球生物技術及製藥服務外包市場規模及趨勢分析（依最終用途）
  • 製藥公司
  • 生技公司

第6章生物技術和製藥服務外包市場：區域估計和趨勢分析，按服務，按最終用途

  • 區域儀表板
  • 生技與醫藥服務外包市場：區域變遷分析
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第7章 競爭格局

  • 公司分類
    • 市場領導者
    • 新興玩家
  • 2023 年企業市場佔有率/估值分析
  • 服務熱圖分析
  • 公司簡介
    • Parexel International Corporation
    • The Quantic Group
    • IQVIA
    • Lachman Consultant Services, Inc.
    • GMP Pharmaceuticals Pty Ltd.
    • Concept Heidelberg GmbH
    • LabCorp
    • Charles River Laboratories
    • ICON plc.
    • Syneos Health
    • Lonza
    • Catalent Inc.
    • Samsung Biologics
Product Code: GVR-1-68038-326-3

Biotechnology And Pharmaceutical Services Outsourcing Market Growth & Trends:

The global biotechnology and pharmaceutical services outsourcing market size is expected to reach USD 66.95 billion by 2030, registering a CAGR of 5.67% from 2024 to 2030, according to a new report by Grand View Research, Inc.

The growing R&D investment for innovative therapeutics by pharmaceutical and biotechnology companies, which are complex and require strict timeline follow-up, is driving outsourcing trend in the industry. Moreover, high costs associated with the new drug development in the biotechnology and pharmaceutical industries lead to customer's preference for cost-effective outsourcing solutions. CROs have the required expertise and infrastructure that provide the benefit of cost, time, and efficiency. Moreover, emerging economies, such as Japan, India, and China are mostly preferred countries for outsourcing activities, owing to strong availability of experts, R&D infrastructure, and affordability.

In addition, regulatory framework for drug discovery and development is complex in several countries. Thus, increasing need for expertise in different areas of drug development is driving the demand for outsourcing services. Drug companies are not only outsourcing production of medicines but also clinical trials. Moreover, the outsourcing of manufacturing activities to developing countries such as China, India, and Latin America is growing due to expanding privatization of clinical trials. Additionally, the globalization of clinical trials has increased the demand for outsourcing services, particularly in emerging markets such as Latin America and MEA owing to large patient pool and lower costs

Regulatory approval procedures are becoming more stringent & time-consuming, and business players aim to receive product approvals at the first attempt to gain a higher market share. Pharmaceutical and biotechnology companies are required to have an in-house regulatory department or outsource their regulatory affairs functions due to stringent regulatory requirements in developed countries and changing regulations in developing countries. Establishing an in-house regulatory affairs department in offshore countries is not feasible, thus companies are adopting different outsourcing models depending upon size and priority of projects, thereby contributing to the growth of global biotechnology/pharmaceutical services outsourcing market.

Pharmaceutical and biotechnology companies are now focusing on their core competencies and outsourcing non-core functions to increase their productivity & operational efficiency. These companies commonly outsource R&D functions to emerging regions, such as Asia Pacific, and have now started outsourcing product design & development to CROs to reduce cost & increase focus on core functions. Small- or mid-sized companies, which do not have in-house capabilities, have to outsource their product design and development, auditing, and regulatory affairs to enter into new markets. Small or specialty companies are hiring CRO consultants to assist in regulatory affairs and legal representation functions in international markets.

Biotechnology And Pharmaceutical Services Outsourcing Market Report Highlights:

  • Based on services, the consulting segment dominated the market in 2023. The high segment growth is driven by increasing changes in regulations by several regulatory authorities such as U.S. FDA and EMA creating the need for regulatory compliance for pharmaceutical & biotech companies. Pharmaceutical and biotech products may face withdrawals, recalls, repacking, or relabeling if products are not compliant with the regulatory standards, thereby preferring consulting services from third party organizations to ensure compliance with evolving regulations
  • Based on end-use, the pharmaceutical companies segment held majority revenue share, accounting of over 58.44% in 2023. Growth in the segment can be attributed to factors such as increase in outsourcing of regulatory services and product design & development services by pharmaceutical companies to avoid high capital expenditure and increase profit margins
  • Asia Pacific dominated the market with a share of 42.41% in 2023. The regional growth is owing to surge in R&D investments by developed countries and numerous regulatory reforms in clinical trial assessment to align with regulatory guidelines of various countries investing in the region

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Details of primary research
  • 1.6. Market Formulation & Validation
  • 1.7. Region-wise Market Calculation
    • 1.7.1. Region-Wise Market: Base Estimates
    • 1.7.2. Global Market: CAGR Calculation
    • 1.7.3. Region Based Segment Share Calculation
  • 1.8. Model Details
    • 1.8.1. Commodity flow analysis (Model 1)
      • 1.8.1.1. Approach 1: Commodity flow approach
    • 1.8.2. Value Chain-Based Sizing & Forecasting (Model 2)
    • 1.8.3. QFD Model Sizing & Forecasting (Model 3)
    • 1.8.4. Bottom-up Approach (Model 4)
  • 1.9. Research Scope and Assumptions
  • 1.10. List of Secondary Sources
  • 1.11. List of Primary Sources
  • 1.12. List of Abbreviations
  • 1.13. Objectives
    • 1.13.1. Objective 1
    • 1.13.2. Objective 2
    • 1.13.3. Objective 3
    • 1.13.4. Objective 4

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Biotechnology and Pharmaceutical Services Outsourcing Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing Outsourcing of R&D Activities
      • 3.2.1.2. Changing Regulatory Landscape
      • 3.2.1.3. Increasing Focus on Core Competencies by Pharmaceutical and Biotechnology Companies
      • 3.2.1.4. Growing Drug Development Costs Coupled With High Clinical Development Failure Rates
      • 3.2.1.5. Increasing Mergers and Collaborations
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Monitoring Issues and Lack of Standardization\
      • 3.2.2.2. Loss of Control
      • 3.2.2.3. Data Security Issues
  • 3.3. Technology Landscape
  • 3.4. Pricing Model Analysis
  • 3.5. Clinical Trials Volume Analysis
  • 3.6. R&D Investment Analysis
  • 3.7. Biotechnology and Pharmaceutical Services Outsourcing Market Analysis Tools
    • 3.7.1. Porter's Five Forces Analysis
    • 3.7.2. PESTEL Analysis
  • 3.8. COVID-19 Impact Analysis

Chapter 4. Biotechnology and Pharmaceutical Services Outsourcing Market: Service Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Biotechnology and Pharmaceutical Services Outsourcing Market: Service Movement Analysis
  • 4.3. Global Biotechnology and Pharmaceutical Services Outsourcing Market Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
  • 4.4. Consulting
    • 4.4.1. Consulting Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.2. Regulatory Consulting
      • 4.4.2.1. Regulatory Consulting Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.3. Clinical Development Consulting
      • 4.4.3.1. Clinical Development Consulting Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.4. Strategic Planning & Business Development Consulting
      • 4.4.4.1. Strategic Planning & Business Development Consulting Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.5. Quality Management Systems Consulting
      • 4.4.5.1. Quality Management Systems Consulting Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.6. Others
      • 4.4.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Regulatory Affairs
    • 4.5.1. Regulatory Affairs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.2. Legal Representation
      • 4.5.2.1. Legal Representation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.3. Regulatory Writing & Publishing
      • 4.5.3.1. Regulatory Writing & Publishing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.4. Product Registration & Clinical Trial Applications
      • 4.5.4.1. Product Registration & Clinical Trial Applications Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.5. Regulatory Submissions
      • 4.5.5.1. Regulatory Submissions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.6. Regulatory Operations
      • 4.5.6.1. Regulatory Operations Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.5.7. Others
      • 4.5.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Product Design & Development
    • 4.6.1. Product Design & Development Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Auditing and Assessment
    • 4.7.1. Auditing and Assessment Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Product Maintenance
    • 4.8.1. Product Maintenance Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.9. Training & Education
    • 4.9.1. Training & Education Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.10. Others
    • 4.10.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Biotechnology and Pharmaceutical Services Outsourcing Market: End-Use Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Biotechnology and Pharmaceutical Services Outsourcing Market: End-Use Movement Analysis
  • 5.3. Global Biotechnology and Pharmaceutical Services Outsourcing Market Size & Trend Analysis, by End-Use, 2018 to 2030 (USD Million)
  • 5.4. Pharmaceutical Companies
    • 5.4.1. Pharmaceutical Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Biotech Companies
    • 5.5.1. Biotech Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Biotechnology and Pharmaceutical Services Outsourcing Market: Regional Estimates & Trend Analysis, by Service, by End-Use

  • 6.1. Regional Dashboard
  • 6.2. Biotechnology and Pharmaceutical Services Outsourcing Market: Regional Movement Analysis
  • 6.3. North America
    • 6.3.1. North America Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Key Country Dynamics
      • 6.3.2.2. Competitive Scenario
      • 6.3.2.3. Regulatory Framework
      • 6.3.2.4. U.S. Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Key Country Dynamics
      • 6.3.3.2. Competitive Scenario
      • 6.3.3.3. Regulatory Framework
      • 6.3.3.4. Canada Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Europe
    • 6.4.1. Europe Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. UK
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Competitive Scenario
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. UK Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Germany
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Competitive Scenario
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Germany Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. France
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Competitive Scenario
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. France Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.5. Italy
      • 6.4.5.1. Key Country Dynamics
      • 6.4.5.2. Competitive Scenario
      • 6.4.5.3. Regulatory Framework
      • 6.4.5.4. Italy Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.6. Spain
      • 6.4.6.1. Key Country Dynamics
      • 6.4.6.2. Competitive Scenario
      • 6.4.6.3. Regulatory Framework
      • 6.4.6.4. Spain Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.7. Denmark
      • 6.4.7.1. Key Country Dynamics
      • 6.4.7.2. Competitive Scenario
      • 6.4.7.3. Regulatory Framework
      • 6.4.7.4. Denmark Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.8. Sweden
      • 6.4.8.1. Key Country Dynamics
      • 6.4.8.2. Competitive Scenario
      • 6.4.8.3. Regulatory Framework
      • 6.4.8.4. Sweden Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.9. Norway
      • 6.4.9.1. Key Country Dynamics
      • 6.4.9.2. Competitive Scenario
      • 6.4.9.3. Regulatory Framework
      • 6.4.9.4. Norway Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Asia Pacific Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. Japan
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Competitive Scenario
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Japan Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. China
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Competitive Scenario
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. China Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. India
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Competitive Scenario
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. India Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Australia
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Competitive Scenario
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Australia Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Thailand
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Competitive Scenario
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Thailand Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. South Korea
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Competitive Scenario
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. South Korea Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Latin America
    • 6.6.1. Latin America Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Brazil
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Competitive Scenario
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Brazil Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. Mexico
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Competitive Scenario
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Mexico Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. Argentina
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Competitive Scenario
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Argentina Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Middle East & Africa
    • 6.7.1. Middle East & Africa Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.2. South Africa
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Competitive Scenario
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. South Africa Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Saudi Arabia
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Competitive Scenario
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Saudi Arabia Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.4. UAE
      • 6.7.4.1. Key Country Dynamics
      • 6.7.4.2. Competitive Scenario
      • 6.7.4.3. Regulatory Framework
      • 6.7.4.4. UAE Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.5. Kuwait
      • 6.7.5.1. Key Country Dynamics
      • 6.7.5.2. Competitive Scenario
      • 6.7.5.3. Regulatory Framework
      • 6.7.5.4. Kuwait Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
    • 7.1.1. Market Leaders
    • 7.1.2. Emerging Players
  • 7.2. Company Market Share/Assessment Analysis, 2023
  • 7.3. Service Heat Map Analysis
  • 7.4. Company Profiles
    • 7.4.1. Parexel International Corporation
      • 7.4.1.1. Company Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Service Benchmarking
      • 7.4.1.4. Strategic Initiatives
    • 7.4.2. The Quantic Group
      • 7.4.2.1. Company Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Service Benchmarking
      • 7.4.2.4. Strategic Initiatives
    • 7.4.3. IQVIA
      • 7.4.3.1. Company Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Service Benchmarking
      • 7.4.3.4. Strategic Initiatives
    • 7.4.4. Lachman Consultant Services, Inc.
      • 7.4.4.1. Company Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Service Benchmarking
      • 7.4.4.4. Strategic Initiatives
    • 7.4.5. GMP Pharmaceuticals Pty Ltd.
      • 7.4.5.1. Company Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Service Benchmarking
      • 7.4.5.4. Strategic Initiatives
    • 7.4.6. Concept Heidelberg GmbH
      • 7.4.6.1. Company Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Service Benchmarking
      • 7.4.6.4. Strategic Initiatives
    • 7.4.7. LabCorp
      • 7.4.7.1. Company Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Service Benchmarking
      • 7.4.7.4. Strategic Initiatives
    • 7.4.8. Charles River Laboratories
      • 7.4.8.1. Company Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Service Benchmarking
      • 7.4.8.4. Strategic Initiatives
    • 7.4.9. ICON plc.
      • 7.4.9.1. Company Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Service Benchmarking
      • 7.4.9.4. Strategic Initiatives
    • 7.4.10. Syneos Health
      • 7.4.10.1. Company Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Service Benchmarking
      • 7.4.10.4. Strategic Initiatives
    • 7.4.11. Lonza
      • 7.4.11.1. Company Overview
      • 7.4.11.2. Financial Performance
      • 7.4.11.3. Service Benchmarking
      • 7.4.11.4. Strategic Initiatives
    • 7.4.12. Catalent Inc.
      • 7.4.12.1. Company Overview
      • 7.4.12.2. Financial Performance
      • 7.4.12.3. Service Benchmarking
      • 7.4.12.4. Strategic Initiatives
    • 7.4.13. Samsung Biologics
      • 7.4.13.1. Company Overview
      • 7.4.13.2. Financial Performance
      • 7.4.13.3. Service Benchmarking
      • 7.4.13.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 4 Global Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 5 Global Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 6 Global Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 7 Global Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 8 Global Biotechnology and Pharmaceutical Services Outsourcing by Region, 2018 - 2030 (USD Million)
  • Table 9 North America Biotechnology and Pharmaceutical Services Outsourcing by Country, 2018 - 2030 (USD Million)
  • Table 10 North America Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 11 North America Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 12 North America Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 13 North America Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 14 North America Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 15 U.S. Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 16 U.S. Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 17 U.S. Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 18 U.S. Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 19 U.S. Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 20 Canada Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 21 Canada Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 22 Canada Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 23 Canada Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 24 Canada Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 25 Europe Biotechnology and Pharmaceutical Services Outsourcing by Country, 2018 - 2030 (USD Million)
  • Table 26 Europe Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 27 Europe Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 28 Europe Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 29 Europe Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 30 Europe Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 31 Germany Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 32 Germany Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 33 Germany Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 34 Germany Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 35 Germany Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 36 U.K. Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 37 U.K. Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 38 U.K. Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 39 U.K. Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 40 U.K. Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 41 France Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 42 France Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 43 France Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 44 France Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 45 France Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 46 Italy Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 47 Italy Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 48 Italy Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 49 Italy Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 50 Italy Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 51 Spain Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 52 Spain Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 53 Spain Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 54 Spain Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 55 Spain Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 56 Denmark Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 57 Denmark Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 58 Denmark Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 59 Denmark Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 60 Denmark Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 61 Sweden Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 62 Sweden Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 63 Sweden Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 64 Sweden Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 65 Sweden Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 66 Norway Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 67 Norway Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 68 Norway Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 69 Norway Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 70 Norway Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 71 Asia Pacific Biotechnology and Pharmaceutical Services Outsourcing by Country, 2018 - 2030 (USD Million)
  • Table 72 Asia Pacific Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 73 Asia Pacific Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 74 Asia Pacific Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 75 Asia Pacific Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 76 Asia Pacific Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 77 China Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 78 China Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 79 China Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 80 China Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 81 China Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 82 Japan Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 83 Japan Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 84 Japan Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 85 Japan Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 86 Japan Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 87 India Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 88 India Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 89 India Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 90 India Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 91 India Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 92 South Korea Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 93 South Korea Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 94 South Korea Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 95 South Korea Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 96 South Korea Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 97 Australia Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 98 Australia Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 99 Australia Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 100 Australia Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 101 Australia Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 102 Thailand Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 103 Thailand Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 104 Thailand Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 105 Thailand Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 106 Thailand Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 107 Latin America Biotechnology and Pharmaceutical Services Outsourcing by Country, 2018 - 2030 (USD Million)
  • Table 108 Latin America Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 109 Latin America Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 110 Latin America Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 111 Latin America Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 112 Latin America Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 113 Brazil Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 114 Brazil Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 115 Brazil Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 116 Brazil Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 117 Brazil Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 118 Mexico Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 119 Mexico Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 120 Mexico Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 121 Mexico Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 122 Mexico Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 123 Argentina Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 124 Argentina Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 125 Argentina Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 126 Argentina Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 127 Argentina Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 128 Middle East & Africa Biotechnology and Pharmaceutical Services Outsourcing by Country, 2018 - 2030 (USD Million)
  • Table 129 Middle East & Africa Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 130 Middle East & Africa Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 131 Middle East & Africa Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 132 Middle East & Africa Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 133 Middle East & Africa Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 134 South Africa Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 135 South Africa Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 136 South Africa Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 137 South Africa Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 138 South Africa Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 139 Saudi Arabia Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 140 Saudi Arabia Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 141 Saudi Arabia Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 142 Saudi Arabia Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 143 Saudi Arabia Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 144 UAE Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 145 UAE Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 146 UAE Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 147 UAE Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 148 UAE Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)
  • Table 149 Kuwait Biotechnology and Pharmaceutical Services Outsourcing by Service, 2018 - 2030 (USD Million)
  • Table 150 Kuwait Biotechnology and Pharmaceutical Services Outsourcing by Consulting Services, 2018 - 2030 (USD Million)
  • Table 151 Kuwait Biotechnology and Pharmaceutical Services Outsourcing by Regulatory Affairs, 2018 - 2030 (USD Million)
  • Table 152 Kuwait Biotechnology and Pharmaceutical Services Outsourcing by Product Design and Development, 2018 - 2030 (USD Million)
  • Table 153 Kuwait Biotechnology and Pharmaceutical Services Outsourcing by End-Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information Procurement
  • Fig. 2 Primary Research Pattern
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 Biotechnology and Pharmaceutical Services Outsourcing, Market Segmentation
  • Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 9 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 10 Porter's Five Forces Analysis
  • Fig. 11 Regional Marketplace: Key Takeaways
  • Fig. 12 Global Biotechnology and Pharmaceutical Services Outsourcing, for Consulting, 2018 - 2030 (USD Million)
  • Fig. 13 Global Biotechnology and Pharmaceutical Services Outsourcing, for Regulatory Consulting, 2018 - 2030 (USD Million)
  • Fig. 14 Global Biotechnology and Pharmaceutical Services Outsourcing, for Clinical Development Consulting, 2018 - 2030 (USD Million)
  • Fig. 15 Global Biotechnology and Pharmaceutical Services Outsourcing, for Strategic Planning & Business Development Consulting, 2018 - 2030 (USD Million)
  • Fig. 16 Global Biotechnology and Pharmaceutical Services Outsourcing, for Quality Management Systems Consulting, 2018 - 2030 (USD Million)
  • Fig. 17 Global Biotechnology and Pharmaceutical Services Outsourcing, for Others, 2018 - 2030 (USD Million)
  • Fig. 18 Global Biotechnology and Pharmaceutical Services Outsourcing, for Regulatory Affairs, 2018 - 2030 (USD Million)
  • Fig. 19 Global Biotechnology and Pharmaceutical Services Outsourcing, for Legal Representation, 2018 - 2030 (USD Million)
  • Fig. 20 Global Biotechnology and Pharmaceutical Services Outsourcing, for Regulatory Writing & Publishing, 2018 - 2030 (USD Million)
  • Fig. 21 Global Biotechnology and Pharmaceutical Services Outsourcing, for Product Registration & Clinical Trial Applications, 2018 - 2030 (USD Million)
  • Fig. 22 Global Biotechnology and Pharmaceutical Services Outsourcing, for Regulatory Submissions, 2018 - 2030 (USD Million)
  • Fig. 23 Global Biotechnology and Pharmaceutical Services Outsourcing, for Regulatory Operations, 2018 - 2030 (USD Million)
  • Fig. 24 Global Biotechnology and Pharmaceutical Services Outsourcing, for Others, 2018 - 2030 (USD Million)
  • Fig. 25 Global Biotechnology and Pharmaceutical Services Outsourcing, for Product Design & Development, 2018 - 2030 (USD Million)
  • Fig. 26 Global Biotechnology and Pharmaceutical Services Outsourcing, for Research, Strategy, & Concept Generation, 2018 - 2030 (USD Million)
  • Fig. 27 Global Biotechnology and Pharmaceutical Services Outsourcing, for Concept & Requirements Development, 2018 - 2030 (USD Million)
  • Fig. 28 Global Biotechnology and Pharmaceutical Services Outsourcing, for Detailed Design & Process Development, 2018 - 2030 (USD Million)
  • Fig. 29 Global Biotechnology and Pharmaceutical Services Outsourcing, for Design Verification & Validation , 2018 - 2030 (USD Million)
  • Fig. 30 Global Biotechnology and Pharmaceutical Services Outsourcing, for Process Validation & Manufacturing Transfer , 2018 - 2030 (USD Million)
  • Fig. 31 Global Biotechnology and Pharmaceutical Services Outsourcing, for Production & Commercial Support, 2018 - 2030 (USD Million)
  • Fig. 32 Global Biotechnology and Pharmaceutical Services Outsourcing, for Pharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 33 Global Biotechnology and Pharmaceutical Services Outsourcing, for Biotech Companies, 2018 - 2030 (USD Million)
  • Fig. 34 Regional Outlook, 2023 & 2030
  • Fig. 35 North America Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 U.S. Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Canada Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Europe Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Germany Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 UK Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 France Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Italy Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Spain Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Denmark Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Sweden Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Norway Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Asia Pacific Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Japan Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 China Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 India Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Australia Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 South Korea Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Thailand Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Latin America Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Brazil Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Mexico Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Argentina Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Middle East and Africa Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 South Africa Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Saudi Arabia Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 UAE Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Kuwait Biotechnology and Pharmaceutical Services Outsourcing Market Estimates and Forecasts, 2018 - 2030 (USD Million)